Forest Labs (FRX) Shares Tick Higher Following Headline of FDA Approval for Chronic Lung Disease Treatment
Tweet
Share
E-mailGet Alerts FRX Hot Sheet
Join SI Premium – FREE
Shares of Forest Labs (NYSE: FRX) have bounced more than a half percent following chatter of FDA approval for its drug to treat chronic lung disease. The stock is still down 1.2 percent to $34.47 at last check.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
